GlassScriptPhysician profile
Peter C Wenger
NPI 1396066627
$1,313.64
in general payments reported to CMS, 2019-2025
20 companies · $362 in 2025
The $362 reported for 2025 was more than what 79% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2021: $111 · 2022: $204 · 2023: $183 · 2024: $248 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $220.97 | 2022-2025 | Gel-One Cross-Linked Hyaluronate |
| Medtronic, INC. | $163.42 | 2025 | Inceptiv |
| Depuy Synthes Sales INC. | $149.28 | 2019-2025 | Orthovisc, Monovisc |
| Boston Scientific Corporation | $114.97 | 2019-2023 | |
| Bioventus LLC | $113.45 | 2019-2025 | Durolane, Xcell |
| Pacira Therapeutics, INC. | $91.59 | 2019-2021 | |
| Fidia Pharma USA INC. | $81.90 | 2021-2024 | Hymovis, Triluron, Hyalgan |
| Si-Bone, INC. | $68.57 | 2022 | |
| Globus Medical, INC. | $55.03 | 2025 | Senza |
| Ferring Pharmaceuticals INC. | $40.14 | 2019 | |
| Novo Nordisk INC | $38.45 | 2022-2024 | Wegovy |
| Kerecis Limited | $37.14 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Ibsa Pharma INC. | $29.21 | 2022-2023 | Tirosint, Licart |
| Glaxosmithkline, LLC. | $18.43 | 2025 | Shingrix |
| Lilly USA, LLC | $18.09 | 2024 | Mounjaro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $15.94 | 2024 | Iovera, Zilretta |
| Sanofi-Aventis U.S. LLC | $14.58 | 2021 | |
| Abbvie INC. | $14.55 | 2024 | |
| Pfizer INC. | $14.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.